Edition:
United States

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

130.25USD
4:00pm EDT
Change (% chg)

$0.67 (+0.52%)
Prev Close
$129.58
Open
$130.01
Day's High
$130.91
Day's Low
$127.47
Volume
191,268
Avg. Vol
470,165
52-wk High
$176.44
52-wk Low
$35.26

Chart for

About

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne... (more)

Overall

Beta: 1.23
Market Cap(Mil.): $8,353.14
Shares Outstanding(Mil.): 66.44
Dividend: --
Yield (%): --

Financials

  SRPT.OQ Industry Sector
P/E (TTM): -- 95.67 30.17
EPS (TTM): -3.37 -- --
ROI: -28.34 3.33 12.67
ROE: -40.19 2.31 14.86

Sarepta shares soar as Duchenne gene therapy shows promise

Sarepta Therapeutics' shares jumped 60 percent on Tuesday after promising results from a gene therapy study positioned the specialty drugmaker as a potential leader in the market for Duchenne muscular dystrophy (DMD) treatments.

Jun 19 2018

UPDATE 3-Sarepta shares soar as Duchenne gene therapy shows promise

* Sarepta shares rise as much as 67.7 percent (Adds details on study results, updates share price)

Jun 19 2018

BRIEF-Sarepta And Invitae Expand Partnership To Advance Clinical Research In Duchenne Muscular Dystrophy

* SAREPTA AND INVITAE EXPAND PARTNERSHIP TO ADVANCE CLINICAL RESEARCH IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage:

May 07 2018

BRIEF-Sarepta Therapeutics Reports Q1 Loss Per Share Of $0.28

* SAREPTA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS

May 03 2018

BRIEF-Sarepta Therapeutics Announces Partnership With Myonexus Therapeutics

* SAREPTA THERAPEUTICS ANNOUNCES PARTNERSHIP WITH MYONEXUS THERAPEUTICS FOR THE ADVANCEMENT OF MULTIPLE GENE THERAPY PROGRAMS AIMED AT TREATING DISTINCT FORMS OF LIMB-GIRDLE MUSCULAR DYSTROPHIES

May 03 2018

BRIEF-Sarepta Therapeutics Inc Says CEO Douglas Ingram's 2017 Total Compensation Was $56.9 Million

* SAREPTA THERAPEUTICS INC SAYS CEO DOUGLAS INGRAM'S 2017 TOTAL COMPENSATION WAS $56.9 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2I3lSGe) Further company coverage:

Apr 26 2018

Sarepta Therapeutics beats bid to revive shareholder class action

A federal appeals court has upheld the dismissal of a lawsuit accusing Sarepta Therapeutics Inc of misleading shareholders by suggesting it had gathered enough data to seek U.S. Food and Drug Administration approval in 2014 to market a treatment for a rare muscle disorder.

Apr 05 2018

BRIEF-Sarepta Therapeutics Announces Plan To Submit A New Drug Application For Accelerated Approval Of Golodirsen

* SAREPTA THERAPEUTICS ANNOUNCES PLAN TO SUBMIT A NEW DRUG APPLICATION (NDA) FOR ACCELERATED APPROVAL OF GOLODIRSEN (SRP-4053) IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) AMENABLE TO SKIPPING EXON 53

Mar 12 2018

BRIEF-Sarepta Therapeutics Reports Q4 Non-GAAP Loss Per Share $0.28

* SAREPTA THERAPEUTICS ANNOUNCES FOURTH QUARTER 2017 AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS

Mar 01 2018

Earnings vs. Estimates